James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Apple Inc. (AAPL): The Luckiest D*mn Company on Earth

Apple stock is benefiting and will continue to benefit from Samsung's glaring error. AAPL investors can count on that.

Why Twitter Inc (TWTR), Bristol-Myers Squibb Co (BMY) and Twilio Inc (TWLO) Are 3 of Today’s Worst Stocks

Twitter (TWTR), Bristol-Myers Squibb (BMY) and Twilio (TWLO) each uses more than their fair share of red ink on Monday.

10 Hot Stocks That Made Millionaires in 10 Years

These 10 names aren't just hot stocks -- they're jaw-dropping, millionaire-making stocks that have earned four-digit returns over the past decade.

Why Tyson Foods, Inc. (TSN), Honeywell International Inc. (HON) and Sarepta Therapeutics Inc (SRPT) Are 3 of Today’s Worst Stocks

The trading week couldn't end soon enough for Tyson Foods (TSN), Sarepta Therapeutics (SRPT) and Honeywell International (HON) shareholders.

Tyson Foods, Inc. (TSN) Deep-Fried Over Antitrust Allegations

Analyst says the antitrust accusations against Tyson Foods (TSN) and others hold a lot of water, even if there's no smoking gun.